CA2591313A1 - Procedes de preparation de composes indazole - Google Patents

Procedes de preparation de composes indazole Download PDF

Info

Publication number
CA2591313A1
CA2591313A1 CA002591313A CA2591313A CA2591313A1 CA 2591313 A1 CA2591313 A1 CA 2591313A1 CA 002591313 A CA002591313 A CA 002591313A CA 2591313 A CA2591313 A CA 2591313A CA 2591313 A1 CA2591313 A1 CA 2591313A1
Authority
CA
Canada
Prior art keywords
formula
compound
alkyl
aryl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002591313A
Other languages
English (en)
Inventor
Srinivasan Babu
Raymond Dagnino, Jr.
Aubrey Haddach
Mark Bryan Mitchell
Michael Allen Ouellette
James Edward Saenz
Jayaram Katsuri Srirangam
Shu Yu
Scott Edward Zook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc.
Srinivasan Babu
Raymond Dagnino, Jr.
Aubrey Haddach
Mark Bryan Mitchell
Michael Allen Ouellette
James Edward Saenz
Jayaram Katsuri Srirangam
Shu Yu
Scott Edward Zook
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc., Srinivasan Babu, Raymond Dagnino, Jr., Aubrey Haddach, Mark Bryan Mitchell, Michael Allen Ouellette, James Edward Saenz, Jayaram Katsuri Srirangam, Shu Yu, Scott Edward Zook filed Critical Pfizer Inc.
Publication of CA2591313A1 publication Critical patent/CA2591313A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA002591313A 2004-11-02 2005-10-21 Procedes de preparation de composes indazole Abandoned CA2591313A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62471904P 2004-11-02 2004-11-02
US60/624,719 2004-11-02
US62480104P 2004-12-14 2004-12-14
US60/624,801 2004-12-14
PCT/IB2005/003348 WO2006048761A2 (fr) 2004-11-02 2005-10-21 Procedes de preparation de composes indazole

Publications (1)

Publication Number Publication Date
CA2591313A1 true CA2591313A1 (fr) 2006-05-11

Family

ID=35456957

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002591313A Abandoned CA2591313A1 (fr) 2004-11-02 2005-10-21 Procedes de preparation de composes indazole

Country Status (9)

Country Link
EP (1) EP1814859A2 (fr)
KR (1) KR20070085727A (fr)
AU (1) AU2005300241A1 (fr)
CA (1) CA2591313A1 (fr)
IL (1) IL183605A0 (fr)
MX (1) MX2007006554A (fr)
RU (1) RU2007120635A (fr)
TW (1) TW200630345A (fr)
WO (1) WO2006048761A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2136284A1 (en) * 1971-02-08 1972-08-31 Diamond Shamrock Corp., Cleveland, Ohio (V.StA.) Herbicidal pyrrolidinyl-carboxanilides - from arylisocyanates and pyrrolidines in organic solvents
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa

Also Published As

Publication number Publication date
IL183605A0 (en) 2007-09-20
WO2006048761A3 (fr) 2006-06-22
TW200630345A (en) 2006-09-01
AU2005300241A1 (en) 2006-05-11
MX2007006554A (es) 2007-06-19
WO2006048761A2 (fr) 2006-05-11
KR20070085727A (ko) 2007-08-27
EP1814859A2 (fr) 2007-08-08
RU2007120635A (ru) 2008-12-10
AU2005300241A2 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
CA2586176A1 (fr) Methodes de preparation de composes d'indazole
CN101094836A (zh) 制备吲唑化合物的方法
EP1797068B1 (fr) Procedes de preparation de 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines substituees
JP2023162264A (ja) 細胞毒性ベンゾジアゼピン誘導体の調製方法
IL197527A (en) History - 4-Oxoquoquinoline and Process and Intermediate Compounds for Preparation of Integration Inhibitors
AU2022201572B2 (en) Methods of preparing cytotoxic benzodiazepine derivatives
CZ2016627A3 (cs) Způsob přípravy (7-fenoxy-4-hydroxy-1-methylisochinolin-3-karbonyl)glycinu (roxadustatu) a jeho intermediátů založený na souběžném otevírání oxazolového kruhu, štěpení etheru a tvorbě iminu
JPH0479349B2 (fr)
CA3044654A1 (fr) Procede de production d'un compose triazolopyridine
JP6256484B2 (ja) ピリダジン化合物の製造方法
JP5017101B2 (ja) 不斉四置換炭素原子含有化合物の製法
CA2591313A1 (fr) Procedes de preparation de composes indazole
CA2975072A1 (fr) Procede de production d'un compose pyrazine carboxamide, et intermediaire de synthese de ce dernier
KR101432427B1 (ko) 요오드 촉매를 이용한 3-하이드록시-2-옥신돌 유도체의 효율적 합성방법
Matsuoka et al. Studies on pyridonecarboxylic acids. V. A practical synthesis of ethyl 6, 7‐difluoro‐1‐methyl‐4‐oxo‐4H‐[1, 3] thiazeto [3, 2‐a] quinoline‐3‐carboxylate, a key intermediate for the new tricyclic quinolone, prulifloxacin (NM441) and versatile new syntheses of the 2‐thioquinoline skeleton
JP5073497B2 (ja) テトラ置換−5−アザスピロ[2.4]へプタン誘導体の製法およびその光学活性中間体
WO2002070477A1 (fr) Acide 2-methylindole-4-acetique, son procede de production et procede pour produire un produit intermediaire de celui-ci
Padwa et al. Intramolecular cyclizations of N-acyliminium ions with pyridine rings
JPH0948778A (ja) 2−置換−3−アルコキシ−5−(ピロール−2−イル)フラン誘導体
JPH0154359B2 (fr)
CN112135820A (zh) 制备二氨基嘧啶衍生物或其酸加成盐的新方法
IL310338A (en) Production method for a synthetic intermediate of a monocyclic pyridine derivative
GB2279346A (en) Benzofuran intermediates
JPH0812670A (ja) 新規なピロリジン誘導体
JP2003221394A (ja) キヌクリジン誘導体の製造方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued